Trial reportInternational journal of psychophysiology : official journal of the International Organization of Psychophysiology2011
Alpha-2 adrenergic challenge with guanfacine one month after mild traumatic brain injury: altered working memory and BOLD response.
Trial report in International journal of psychophysiology : official journal of the International Organization of Psychophysiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- A translational investigation targeting stress-reactivity and prefrontal cognitive control with guanfacine for smoking cessation.Journal of psychopharmacology (Oxford, England) · 2015Trial
- Guanfacine and HCN channels: bridging neuroinflammation and prefrontal cortex function in autism spectrum disorder.Frontiers in molecular neuroscience · 2026Review
- A stratified precision medicine trial targeting αNature. Mental health · 2025Article
- A novel multimodal pharmacologic approach using guanfacine, N-acetylcysteine, and donepezil in severe TBI: a case series.Frontiers in rehabilitation sciences · 2025Article
- Long-Term Impact of Diffuse Traumatic Brain Injury on Neuroinflammation and Catecholaminergic Signaling: Potential Relevance for Parkinson's Disease Risk.Molecules (Basel, Switzerland) · 2024Article
- Combined Use of Guanfacine andNeurotrauma reports · 2024Article
- Navigating the Complexities of Traumatic Encephalopathy Syndrome (TES): Current State and Future Challenges.Biomedicines · 2023Review
- Scientific rationale for the use of α2A-adrenoceptor agonists in treating neuroinflammatory cognitive disorders.Molecular psychiatry · 2023Review
- Scientific Rationale for the Treatment of Cognitive Deficits from Long COVID.Neurology international · 2023Review
- A Systematic Review of Treatments of Post-Concussion Symptoms.Journal of clinical medicine · 2022Review
- Multimodal MRI examination of structural and functional brain changes in older women with breast cancer in the first year of antiestrogen hormonal therapy.Breast cancer research and treatment · 2022Observational
- ENIGMA brain injury: Framework, challenges, and opportunities.Human brain mapping · 2022Review
- Differential Effects of Pergolide and Bromocriptine on Working Memory Performance and Brain Activation after Mild Traumatic Brain Injury.Journal of neurotrauma · 2021Article
- Clinical Practice: Should we Radically Alter our Sedation of Critical Care Patients, Especially Given the COVID-19 Pandemics?Romanian journal of anaesthesia and intensive care · 2020Article
- Guanfacine's mechanism of action in treating prefrontal cortical disorders: Successful translation across species.Neurobiology of learning and memory · 2020Review
- Methylphenidate Treatment of Cognitive Dysfunction in Adults After Mild to Moderate Traumatic Brain Injury: Rationale, Efficacy, and Neural Mechanisms.Frontiers in neurology · 2019Review
- Untangling PTSD and TBI: Challenges and Strategies in Clinical Care and Research.Current neurology and neuroscience reports · 2018Review
- Executive (dys)function after traumatic brain injury: special considerations for behavioral pharmacology.Behavioural pharmacology · 2018Review
- Cholinergic, But Not Dopaminergic or Noradrenergic, Enhancement Sharpens Visual Spatial Perception in Humans.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2017Article
- Assessment of cognitive dysfunction in traumatic brain injury patients: a review.Forensic sciences research · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Alterations in working memory (WM) are common after traumatic brain injury (TBI). Frontal catecholaminergic systems, including the alpha-2 adrenergic system, modulate WM function and may be affected in TBI. We hypothesized that administration of an alpha-2 adrenergic agonist might improve WM after mild TBI (MTBI). Thirteen individuals with MTBI 1month after injury and 14 healthy controls (HC) were challenged with guanfacine and placebo prior to administration of a verbal WM functional MRI task. Guanfacine was associated with improved WM performance in the MTBI but not the HC group. On guanfacine the MTBI group showed increased activation within a WM task-specific region of interest. Findings are consistent with the hypothesis that alterations in WM after MTBI may be improved with the alpha-2 agonist guanfacine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.